Abstract
Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have